This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Beijing Biostar Pharmaceuticals Co., Ltd., Chengdu Biostar Pharmaceuticals, Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Rixiang Kong: Innovator in Pharmaceutical Crystallization
Introduction
Rixiang Kong is a notable inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative crystal forms for drug formulations. His work focuses on enhancing the stability and efficacy of pharmaceutical compounds.
Latest Patents
Rixiang Kong holds a patent for the "Utidelone semi-hydrated single crystal and preparation method therefor and use thereof." This invention pertains to a polycrystal form of Utidelone, specifically a semi-hydrated crystal form that is stable and resistant to high temperature and humidity. The preparation method is both diversified and simple, making it suitable for the industrialized production of new medicines. This crystal form is particularly useful in the preparation of pharmaceutical compositions aimed at inhibiting tumor growth and treating solid tumors in mammals, especially humans.
Career Highlights
Throughout his career, Rixiang Kong has worked with prominent companies in the pharmaceutical industry, including Chengdu Biostar Pharmaceuticals, Ltd. and Beijing Biostar Pharmaceuticals Co., Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical development and innovation.
Collaborations
Rixiang Kong has collaborated with notable colleagues such as Li Tang and Rongguo Qiu. These partnerships have further enriched his research and development efforts in the pharmaceutical sector.
Conclusion
Rixiang Kong's contributions to the field of pharmaceuticals, particularly through his innovative patent on Utidelone, highlight his role as a key inventor in the industry. His work not only advances drug formulation techniques but also holds promise for improving cancer treatment options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile